· Male
· Multidisciplinary Team(s)
· Hematologic (Malignant)
· Department/Research Program(s)
· Department of Oncology
· Cancer Type(s)
· Hodgkin's Lymphoma
Leukemia
Lymphoma
Non-Hodgkin's Lymphoma
· Contact Info
· Email:
ramchanr@karmanos.org
· Education
· Fellowship
Hematology-Oncology, St. John Health Systems, Providence Hospital
Medical School
Ross University School of Medicine
Residency
Drexel Univeristy College of Medicine - Habnemann University, Philadelphia, PA
· Professional Memberships/Associations
· American Society of Hematology
American Society of Clinical Oncology
American College of Physicians
· Board Certifications
· American Board of Internal Medicine
· Clinical Interests
· Hematology Oncology
· Research Interests
· Lymphoma and myeloma
· Publications
· Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) for Patients with Relapsed or Refractory Hodgkin Lymphoma. Authors: Anas Younes, Ajay K Gopal, Scott E. Smith, Stephen M Ansell, Joseph D Rosenblatt, Kerry J Savage, Radhakrishnan Ramchandren, Nancy L Bartlett, Bruce D Cheson, Sven de Vos1, Andres Forero-Torres, Craig H Moskowitz, Joseph M Connors, Andreas Engert, Emily K Larsen, Dana A Kennedy, Eric L Sievers, and Robert Chen. Journal of Clinical Oncology. In press 2011
Advances in the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma. The oncologist in press 2011 Author: R. Ramchandren.
Cryptococcus Albidus Infection in a Patient Undergoing Autologous Progenitor Cell Transplant. Transplantation. 2004;77(6):956 Authors: Ramchandren R, Gladstone D.
Dasatinib treatment of imatinib resistant CML. Biologics Target and Therapy. Biologics. 2009;3:205-14. Authors: Ramchandren R, Schiffer CA.
2. 备注【癌种】进病友群
扫描预约专家问诊